Alpha Tau Medical (DRTS) Research & Development (2021 - 2026)

Alpha Tau Medical has disclosed Research & Development across 6 years of filings, most recently posting $11.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $11.0 million, up 53.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.9 million (up 29.3% YoY), and the FY2025 annual result was $32.1 million, up 18.67% from the prior year.
• Research & Development came in at $11.0 million for Q1 2026 at Alpha Tau Medical, up from $9.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $11.0 million in Q1 2026 to a low of $4.8 million in Q3 2022.
• The 5-year median for Research & Development is $6.7 million (2023), against an average of $6.9 million.
• Across the five-year window, Research & Development soared 139.15% in 2022 and retreated 7.49% in 2024, its largest moves.
• Alpha Tau Medical's Research & Development stood at $5.4 million in 2022, then soared by 39.22% to $7.5 million in 2023, then advanced by 0.57% to $7.5 million in 2024, then rose by 27.12% to $9.6 million in 2025, then grew by 14.61% to $11.0 million in 2026.
• The last three Research & Development figures came in at $11.0 million (Q1 2026), $9.6 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.